BCM
Boxer Capital Management Portfolio holdings
AUM
$199M
This Quarter Return
+89.98%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$199M
AUM Growth
+$199M
(-40%)
Cap. Flow
-$195M
Cap. Flow
% of AUM
-98.11%
Top 10 Holdings %
Top 10 Hldgs %
91.42%
Holding
36
New
8
Increased
3
Reduced
7
Closed
16
Top Buys
| 1 |
iTeos Therapeutics
ITOS
|
$8.23M |
| 2 |
UroGen Pharma
URGN
|
$7.88M |
| 3 |
CBIO
Crescent Biopharma, Inc. Common Stock
CBIO
|
$7.32M |
| 4 |
Kymera Therapeutics
KYMR
|
$4.67M |
| 5 |
Replimune Group
REPL
|
$3.86M |
Top Sells
| 1 |
Nuvalent
NUVL
|
$31.9M |
| 2 |
Avidity Biosciences
RNA
|
$25.5M |
| 3 |
AnaptysBio
ANAB
|
$24.2M |
| 4 |
Xenon Pharmaceuticals
XENE
|
$20.1M |
| 5 |
Revolution Medicines
RVMD
|
$19.3M |
Sector Composition
| 1 | Healthcare | 99.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Tango Therapeutics
TNGX
$747M
| $50M | 25.18% | 9,771,485 -609,514 | -6% | -$3.12M |
|
|
2
Revolution Medicines
RVMD
$7.1B
| $29.2M | 14.69% | 792,977 -525,000 | -40% | -$19.3M |
|
|
3
Replimune Group
REPL
$422M
| $20.5M | 10.34% | 2,211,341 +415,000 | +23% | +$3.86M |
|
4
Merus
MRUS
$4.98B
| $19.2M | 9.66% | 365,000 -335,000 | -48% | -$17.6M |
|
|
5
Kymera Therapeutics
KYMR
$2.95B
| $18.9M | 9.49% | 432,010 +107,010 | +33% | +$4.67M |
|
6
uniQure
QURE
$896M
| $12.5M | 6.31% | 899,500 +149,500 | +20% | +$2.08M |
|
|
7
iTeos Therapeutics
ITOS
| $8.23M | 4.14% | +825,000 | New | +$8.23M |
|
|
8
UroGen Pharma
URGN
$900M
| $7.88M | 3.97% | +575,000 | New | +$7.88M |
|
9
Amylyx Pharmaceuticals
AMLX
$836M
| $7.85M | 3.95% | 1,225,000 -525,000 | -30% | -$3.37M |
|
|
CBIO
10
Crescent Biopharma, Inc. Common Stock
CBIO
$200M
| $7.32M | 3.69% | +453,686 | New | +$7.32M |
|
11
Protagonist Therapeutics
PTGX
$3.67B
| $3.32M | 1.67% | +60,000 | New | +$3.32M |
|
12
Nektar Therapeutics
NKTR
$568M
| $3.23M | 1.63% | +125,000 | New | +$3.23M |
|
13
Kodiak Sciences
KOD
$478M
| $2.8M | 1.41% | 750,000 -285,000 | -28% | -$1.06M |
|
14
Cidara Therapeutics
CDTX
$1.66B
| $2.68M | 1.35% | +55,000 | New | +$2.68M |
|
15
Nurix Therapeutics
NRIX
$714M
| $1.99M | 1% | 175,000 -388,067 | -69% | -$4.42M |
|
16
Instil Bio
TIL
$182M
| $1.47M | 0.74% | 70,700 -9,425 | -12% | -$196K |
|
17
KalVista Pharmaceuticals
KALV
$678M
| $1.06M | 0.53% | +93,400 | New | +$1.06M |
|
18
Sarepta Therapeutics
SRPT
$1.78B
| $428K | 0.22% | +25,000 | New | +$428K |
|
19
Nuvation Bio Inc. Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50
NUVB.WS
$68M
| $72K | 0.04% | 266,666 | – | – |
|
20
Surrozen, Inc. Warrant
SRZNW
$71.6K
| $1.21K | ﹤0.01% | 66,666 | – | – |
|
|
21
AnaptysBio
ANAB
$569M
| – | – | -1,300,000 | Closed | -$24.2M |
|
22
Apellis Pharmaceuticals
APLS
$3.48B
| – | – | -713,000 | Closed | -$15.6M |
|
23
Day One Biopharmaceuticals
DAWN
$769M
| – | – | -1,189,943 | Closed | -$9.44M |
|
24
Denali Therapeutics
DNLI
$2.23B
| – | – | -250,000 | Closed | -$3.4M |
|
25
Enliven Therapeutics
ELVN
$1.2B
| – | – | -671,358 | Closed | -$13.2M |
|